
GLP-1s and employer health plans: Navigating coverage, usage, and cost challenges
GLP-1s have quickly emerged as the fastest-growing drug class in the U.S., with spending surpassing a whopping $70 billion in 2023. Although originally developed for diabetes, demand has continued to rise as consumers have found it to also be an effective weight-loss treatment. Employers are now facing growing pressure ...